Last reviewed · How we verify
NCT03865186
An Evaluation of a Psychoeducation Program in Individuals Diagnosed With Schizophrenia
NA trial testing Psychoeducation Program in Schizophrenia in 42 participants. Completed in 15 July 2016.
30 October 2015
Quick facts
| Lead sponsor | Kırıkkale University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 42 |
| Start date | 1 January 2015 |
| Primary completion | 30 October 2015 |
| Estimated completion | 15 July 2016 |
Drugs / interventions tested
- Psychoeducation Program
- no intervention
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Kırıkkale University
Who can join
Adults 18 to 60, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was conducted to explore the effect on social functionality of the psychoeducation program organized to guide individuals diagnosed with schizophrenia to identifying and recognize emotions in facial expressions. half of participants were assessed the psychoeducation program. other half of participants were used only measurement tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03865186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Psychoeducation Program
Trials testing the same drug.
- NCT07274592 — The Effect of Psychoeducation Program Applied to Older Adults Based on Psychosocial Development Theory on Self-critical · NA · completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Kırıkkale University trials
Trials by the same sponsor.
- NCT07323420 — Effects of Different Inspiratory:Expiratory Ratios on Respiratory and Recovery Outcomes During Dental Procedures Under G · recruiting
- NCT07504861 — Biomarkers in Apical Periodontitis · not yet recruiting
- NCT07451860 — Chronic Total Occlusion and Triglyceride-Glucose Index · not yet recruiting
- NCT06921369 — The Effect of Compassionate Care Education on Nurses · NA · not yet recruiting
- NCT07338253 — The Effect of the Flipped Learning Model on Spiritual Care Perception and Competence in Nursing Students · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03865186 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kırıkkale University
- Last refreshed: 6 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03865186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing